Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Kazia Therapeutics Ltd

KZIA ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$8.04

▼ -8.74%

Market Cap $122.58M · Vol 71.35K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$122.58M

Micro Cap

Div Yield

N/A

EPS Growth

+79.21%

YoY

RSI (14)

21.32

Momentum

Beta

2.33

vs Market

52W High

$17.30

53.53% below

52W Low

$4.91

63.75% above

Volume

71.35K

Avg 65.25K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

84.50%

Public shares

Shariah Compliance8 STANDARDS

✗ Kazia Therapeutics Ltd (KZIA) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does KZIA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-13.17%

-28.15%

-40.84%

-10.57%

YTD

+16.69%

+18.06%

-76.35%

-98.52%

Financials & Valuation

TTM · Annual

Total Revenue	$75.01K
Net Income	$-13,621,888.00
Revenue Growth (YoY)	+456.88%
Gross Margin	100.00%
Operating Margin	-13,975.44%
Net Profit Margin	-18,159.65%
ROE	N/A
ROA · ROIC	-162.40% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	465.76
P/B	N/A
P/FCF	N/A
EPS Growth	+79.21%
Outstanding Shares	7.62B

Technical Indicators

50-Day SMA	$11.65
200-Day SMA	$10.45
RSI (14)	21.32
Beta	2.33
52-Week High	$17.30
52-Week Low	$4.91

Volume Today	71.35K
Avg Daily Volume (30D)	65.25K
Relative Volume	1.09x
Volatility (10D)	46.74
Volatility (30D)	63.96
Free Float	84.50%

Analyst Consensus

BUY

Current Price $8.04

Mean Target $26.50

52W Low$4.91 52W High$17.30

Current

Target

$4.91 $17.30

Current Analyst target

+229.60% upside potential · 6 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SCPMJ4

ISINUS48669G3039

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.32% ONC BeOne Medicines AG -0.38% 068270.KS Celltrion, Inc. -0.39% MEDP Medpace Holdings, Inc. -1.64% ABVX Abivax SA -0.83%

Company Profile

Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.